Novo Shares Slump on Pricing Concerns
Novo Nordisk shares dropped after executives faced tough questions over pricing power and dealmaking strategy. Analysts expressed skepticism regarding the drugmaker's 2030 sales outlook and looming patent expiries for Wegovy.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B shares dropped 4.4% on Monday in London after executives faced tough investor questions regarding pricing power and upcoming patent expiries. The drop adds to a 70% slide from record highs, driven by competition from United States rival ELI LILLY & CO in the anti-obesity market.
